Differentiated Thyroid Cancer (DTC) Recruiting Phase 1 / 2 Trials for Atezolizumab (DB11595)

Also known as: Differentiated Thyroid Cancer

IndicationStatusPhase
DBCOND0062237 (Differentiated Thyroid Cancer (DTC))Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03170960Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsTreatment